Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intra-Cellular Therapies (Research Report).
Intra-Cellular Therapies (ITCI)
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies, with a price target of $70.00. The company’s shares closed last Wednesday at $58.87.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $71.13 average price target, a 24.1% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $90.00 price target.
Axsome Therapeutics (AXSM)
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Axsome Therapeutics today and set a price target of $55.00. The company’s shares closed last Wednesday at $46.49, close to its 52-week high of $47.49.
Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $69.11.
Treace Medical Concepts (TMCI)
Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Treace Medical Concepts today and set a price target of $23.00. The company’s shares closed last Wednesday at $19.40.
Treace Medical Concepts has an analyst consensus of Strong Buy, with a price target consensus of $22.33, a 17.5% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $23.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ITCI:
- Analysts Offer Insights on Services Companies: ARAMARK Holdings (ARMK), Warner Music Group (WMG) and Sweetgreen (SG)
- Chardan Capital Sticks to Their Buy Rating for Kodiak Sciences (KOD)
- First Watch Restaurant Group (FWRG) Gets a Buy from Goldman Sachs
- Credit Suisse Sticks to Its Buy Rating for Hims & Hers Health (HIMS)
- Morgan Stanley Sticks to Its Hold Rating for RealReal (REAL)